Indian pharma and healthcare deal value held at about $13.9 billion in Q1 FY27 and Q2 2026 despite a decline in deal volumes, led by Sun Pharmaceutical Industries’ $11.8 billion acquisition of Organon & Co. and a clear shift toward specialty portfolios, global market access, and differentiated capabilities, with investor interest centering on AI-enabled care, genomics, oncology, and advanced diagnostics, and outbound M&A accounting for the vast majority of activity.
